Confronting complexity in late-onset Alzheimer disease: Application of two-stage analysis approach addressing heterogeneity and epistasis

Genetic Epidemiology

Volumn 32, Issue 3, 2008, Pages 187-203

  Thornton Wells, Tricia A ^a   Moore, Jason H ^b   Martin, Eden R ^c   Pericak Vance, Margaret A ^c   Haines, Jonathan L ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Association; Bayesian classification; Clustering; Complex disease; Epistasis; Gene gene interaction; Heterogeneity; Linkage; Logistic regression; Multifactor dimensionality reduction; Statistical genetics

Indexed keywords

CELL CYCLE PROTEIN; CELL DIVISION CYCLE 2; DIPEPTIDYL CARBOXYPEPTIDASE; LEUCINE RICH REPEAT TRANSMEMBRANE NEURONAL 3; NERVE PROTEIN; UNCLASSIFIED DRUG; UROKINASE;

ALZHEIMER DISEASE; ARTICLE; BAYES THEOREM; CHROMOSOME 10; CONTROLLED STUDY; EPISTASIS; GENE CLUSTER; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; CLUSTER ANALYSIS; DATABASES, GENETIC; EPISTASIS, GENETIC; FAMILY; GENETIC HETEROGENEITY; GENETIC MARKERS; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS;

EID: 42249095648     PISSN: 07410395     EISSN: 10982272     Source Type: Journal    
DOI: 10.1002/gepi.20294     Document Type: Article

References (77)

1. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. 2005. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25:5446-5454.
2. Bagli M, Papassotiropoulos A, Jessen F, Rao ML, Maier W, Heun R. 2000. Gene-gene interaction between interleukin-6 and alpha2-macroglobulin influences the risk for Alzheimer's disease. Ann Neurol 47:138-139.
3. Bagnoli S, Tedde A, Cellini E, Rotondi M, Nacmias B, Sorbi S. 2005. The urokinase-plasminogen activator (PLAU) gene is not associated with late onset Alzheimer's disease. Neurogenetics 6:53-54.
4. Barrett JC, Fry B, Mailer J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265.
5. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57:289-300.
6. Bertram L, Hsiao M, McQueen MB, Parkinson M, Mullin K, Blacker D, Tanzi RE. 2007a. The LDLR locus in Alzheimer's disease: a family-based study and meta-analysis of case-control data. Neurobiol Aging 28:18.e18-18.e21.
7. Bertram L, Mullin K, Parkinson M, Hsiao M, Moscarillo TJ, Wagner SL, Becker KD, Velicelebi G, Blacker D, Tanzi RE. 2007b. Is alpha-T catenin (VR22) an Alzheimer's disease risk gene?. J Med Genet 44:e63.
8. Blomqvist ME, Andreasen N, Bogdanovic N, Blennow K, Brookes AJ, Prince JA. 2004. Genetic variation in CTNNA3 encoding alpha-3 catenin and Alzheimer's disease. Neurosci Lett 358:220-222.
9. Cheeseman P, Stutz J. 1996. Bayesian Classification (AutoClass): Theory and Results. Menlo Park: The American Association of Artificial Intelligence/MIT Press.
10. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George HP, Selkoe DJ. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3:67-72.
11. Corder EH, Beaumont H. 2007. Susceptibility groups for Alzheimer's disease (OPTIMA cohort): integration of gene variants and biochemical factors. Mech Ageing Dev 128:76-82.
12. Corder EH, Woodbury MA. 1993. Genetic heterogeneity in Alzheimer's disease: a grade of membership analysis. Genet Epidemiol 10:495-499.
13. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
14. Cruts M, Backhovens H, Wang SY, Van Gassen G, Theuns J, De Jonghe CD, Wehnert A, De Voecht J, De Winter G, Cras P. 1995. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum Mol Genet 4:2363-2371.
15. Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM. 2000. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 66:196-204.
16. Cruts M, Backhovens H, Wang SY, Van Gassen G, Theuns J, De Jonghe CD, Wehnert A, De Voecht J, De Winter G, Cras P, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM. 1995. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 66:196-204.
17. Ditter SM, Mirra SS. 1987. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 37:754-760.
18. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-Tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713.
19. Ertekin-Taner N, Ronald J, Asahara H, Younkin L, Hella M, Jain S, Gnida E, Younkin S, Fadale D, Ohyagi Y, Singleton A, Scanlin L, de AM, Petersen R, Graff-Radford N, Hutton M, Younkin S. 2003. Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Hum Mol Genet 12:3133-3143.
20. Ertekin-Taner N, Ronald J, Feuk L, Prince J, Tucker M, Younkin L, Hella M, Jain S, Hackett A, Scanlin L, Kelly J, Kihiko-Ehman M, Neltner M, Hersh L, Kindy M, Markesbery W, Hutton M, de Andrade M, Petersen RC, Graff-Radford N, Estus S, Brookes AJ, Younkin SG. 2005. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet 14:447-460.
21. Finckh U, van Hadeln K, Muller-Thomsen T, Alberici A, Binetti G, Hock C, Nitsch RM, Stoppe G, Reiss J, Gal A. 2003. Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2 Neurogenetics 4:213-217.
22. Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, Yang H, Ch'ang LY, Huang W, Liu B, Shen Y, Tam PK, Tsui LC, Waye MM, Wong JT, Zeng C, Zhang Q, Chee MS, Galver LM, Kruglyak S, Murray SS, Oliphant AR, Montpetit A, Hudson TJ, Chagnon F, Ferretti V, Leboeuf M, Phillips MS, Verner A, Kwok PY, Duan S, Lind DL, Miller RD, Rice JP, Saccone NL, Taillon-Miller P, Xiao M, Nakamura Y, Sekine A, Sorimachi K, Tanaka T, Tanaka Y, Tsunoda T, Yoshino E, Bentley DR, Deloukas P, Hunt S, Powell D, Altshuler D, Gabriel SB, Zhang H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Aniagwu T, Marshall PA, Matthew O, Nkwodimmah C, Royal CD, Leppert MF, Dixon M, Stein LD, Cunningham F, Kanani A, Thorisson GA, Chakravarti A, Chen PE, Cutler DJ, Kashuk CS, Donnelly P, Marchini J, McVean GA, Myers SR, Cardon LR, Abecasis GR, Morris A, Weir BS, Mullikin JC, Sherry ST, Feolo M, Altshuler D, Daly MJ, Schaffner SF, Qiu R, Kent A, Dunston GM, Kato K, Niikawa N, Knoppers BM, Foster MW, Clayton EW, Wang VO, Watkin J, Gibbs RA, Belmont JW, Sodergren E, Weinstock GM, Wilson RK, Fulton LL, Rogers J, Birren BW, Han H, Wang H, Godbout M, Wallenburg JC, L'Archeveque P, Bellemare G, Todani K, Fujita T, Tanaka S, Holden AL, Lai EH, Collins FS, Brooks LD, McEwen JE, Guyer MS, Jordan E, Peterson JL, Spiegel J, Sung LM, Zacharia LF, Kennedy K, Dunn MG, Seabrook R, Shillito M, Skene B, Stewart JG, Valle DL, Jorde LB, Belmont JW, Chakravarti A, Cho MK, Duster T, Foster MW, Jasperse M, Knoppers BM, Kwok PY, Licinio J, Long JC, Marshall PA, Ossorio PN, Wang VO, Rotimi CN, Royal CD, Spallone P, Terry SF, Lander ES, Lai EH, Nickerson DA, Altshuler D, Bentley DR, Boehnke M, Cardon LR, Daly MJ, Deloukas P, Douglas JA, Gabriel SB, Hudson RR, Hudson TJ, Kruglyak L, Kwok PY, Nakamura Y, Nussbaum RL, Royal CD, Schaffner SF, Sherry ST, Stein LD, Tanaka T. 2003. The International HapMap Project. Nature 426:789-796.
23. Glabe C. 2000. Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation? Nat Med 6:133-134.
24. Goedert M. 1999. Pinning down phosphorylated tau. Nature 399:739-740.
25. Growden JH. 1995. Advances in the diagnosis of Alzheimer's Disease. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski H, editors. Research Advances in Alzheimer's Disease and Related Disorders. New York: Wiley, p 139-153.
26. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. 2003. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60:729-736.
27. Hahn LW, Ritchie MD, Moore JH. 2003. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19:376-382.
28. Hahn LW, Edwards TL, Gilbert JR, Pericak-Vance MA, Martin ER, Ritchie MD. 2006. Gene-gene interaction models identified for Alzheimer Disease using MDR-PDT [Abstract 2224]. Annual Meeting of The American Society of Human Genetics, October 12, 2006, New Orleans, LA. Available from http://www.ash-g. org/genetics/ashg06s/index.shtml.
29. Hanson R, Stutz J, Cheeseman P. 1991. Bayesian classification theory. In: Technical Report FIA-90-12-7-01. Artificial Intelligence Branch, NASA Ames Research Center.
30. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. 2002. A comprehensive review of genetic association studies. Genet Med 4:45-61.
31. Hu J, Miyatake F, Aizu Y, Nakagawa H, Nakamura S, Tamaoka A, Takahash R, Urakami K, Shoji M. 1999. Angiotensin-Converting enzyme genotype is associated with Alzheimer disease in the Japanese population. Neurosci Lett 277:65-67.
32. Hu J, Igarashi A, Kamata M, Nakagawa H. 2001. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276:47863-47868.
33. Janssens B, Goossens S, Staes K, Gilbert B, van Hengel J, Colpaert C, Bruyneel E, Mareel M, van Roy F. 2001. AlphaT-catenin: a novel tissue-specific beta-catenin-binding protein mediating strong cell-cell adhesion. J Cell Sci 114:3177-3188.
34. Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N, Sjogren M, Zetterberg H, Forsell L, Lilius L, Wahlund LO, Rymo L, Prince JA, Blennow K. 2003. Increased frequency of a new polymorphism in the cell division cycle 2 (CDC2) gene in patients with Alzheimer's disease and frontotemporal dementia. Neurosci Lett 340:69-73.
35. Johansson A, Zetterberg H, Hampel H, Buerger K, Prince JA, Minthon L, Wahlund LO, Blennow K. 2005. Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease. Dement Geriatr Cogn Disord 20:367-374.
36. Lauren J, Airaksinen MS, Saarma M, Timmusk T. 2003. A novel gene family encoding leucine-rich repeat transmembrane proteins differentially expressed in the nervous system. Genomics 81:411-121.
37. Liang X, Martin ER, Schnetz-Boutaud N, Bartlett J, Anderson B, Zuchner S, Gwirtsman H, Schmechel D, Carney R, Gilbert JR, Pericak-Vance MA, Haines JL. 2007a. Effect of heterogeneity on the chromosome 10 risk in late-onset Alzheimer disease. Hum Mutat 28:1065-1073.
38. Liang X, Schnetz-Boutaud N, Bartlett J, Anderson BM, Gwirtsman H, Schmechel D, Carney R, Gilbert JR, Pericak-Vance MA, Haines JL. 2007b. Association analysis of genetic polymorphisms in the CDC2 gene with late-onset Alzheimer disease. Dement Geriatr Cogn Disord 23:126-132.
39. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. 2006a. "Flip-flop" associations: confirmation or spurious findings? [Abstract 1528]. Annual Meeting of The American Society of Human Genetics, October 12, 2006, New Orleans, LA. Available from http://www.ashg.org/genetics/ashg06s/ index.shtml
40. Lin PI, Martin ER, Browning-Large CA, Schmechel DE, Welsh-Bohmer KA, Doraiswamy PM, Gilbert JR, Haines JL, Pericak-Vance MA. 2006b. Parsing the genetic heterogeneity of chromosome 12q susceptibility genes for Alzheimer disease by family-based association analysis. Neurogenetics 7:157-165.
41. Martin ER, Monks SA, Warren LL, Kaplan NL. 2000. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am J Hum Genet 67:146-154.
42. Martin ER, Bass MP, Kaplan NL. 2001. Correcting for a potential bias in the pedigree disequilibrium test. Am J Hum Genet 68:1065-1067.
43. Martin ER, Bronson PG, Li YJ, Wall N, Chung RH, Schmechel DE, Small G, Xu PT, Bartlett J, Schnetz-Boutaud N, Haines JL, Gilbert JR, Pericak-Vance MA. 2005. Interaction between the alpha-T catenin gene (VR22) and APOE in Alzheimer's disease. J Med Genet 42:787-792.
44. Martin ER, Ritchie MD, Hahn L, Kang S, Moore JH. 2006. A novel method to identify gene-gene effects in nuclear families: the MDR-PDT. Genet Epidemiol 30:111-123.
45. Mateo I, Infante J, Rodriguez E, Berciano J, Combarros O, Llorca J. 2006. Interaction between dopamine beta-hydroxylase and interleukin genes increases Alzheimer's disease risk. J Neurol Neurosurg Psychiatry 77:278-279.
46. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124.
47. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos MJ, O'Brien J, Playfer J, Reid W. 2004. Dementia with Lewy bodies. Lancet Neurol 3:19-28.
48. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
49. McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, Manly SP, Kozlowski MR, Neve KA, Neve RL. 2003. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci 23:6914-6927.
50. Metzler-Baddeley C. 2007. A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer's disease and Parkinson's disease with dementia. Cortex 43:583-600.
51. Meyer JS, Huang J, Chowdhury MH. 2007. MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. J Neurol Sci 257:97-104.
52. Moore JH. 2007. Genome-wide analysis of epistasis using multifactor dimensionality reduction: feature selection and construction in the domain of human genetics. In: Zhu X, Davidson I, editors. Knowledge Discovery and Data Mining: Challenges and Realities. Hersey, PA: IGI Global.
53. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, Barney N, White BC. 2006. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 241:252-261.
54. Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. 1999. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 158:469-490.
55. Olson JM, Goddard KA, Dudek DM. 2002. A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum Genet 71:154-161.
56. Ott J. 1999. Analysis of Human Genetic Linkage. Baltimore: Johns Hopkins University Press.
57. Ott J, Hoh J. 2003. Set association analysis of SNP case-control and microarray data. J Comput Biol 10:569-574.
58. Pei JJ, An WL, Zhou XW, Nishimura T, Norberg J, Benedikz E, Gotz J, Winblad B. 2006. P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett 580:107-114.
59. Pericak-Vance MA, Haines JL. 2002. The genetics of Alzheimer Disease. In: King RA, Rotter JI, Motulsky AG, editors. The Genetic Basis of Common Diseases. Oxford: Oxford University Press.
60. Pesaresi M, Batelli S, Prato F, Polito L, Lovati C, Scarpini E, Quadri P, Mariani C, Albani D, Forloni G. 2007. The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level. Neurobiol Dis 25:609-613.
61. Pritchard JK, Stephens M, Donnelly P. 2000. Inference of population structure using multilocus genotype data. Genetics 155:945-959.
62. Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, Chen HY, Van de Ploeg LH, Zheng H. 1998. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. Neuron 20:611-617.
63. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Pari FF, Moore JH. 2001. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69:138-147.
64. Ritchie MD, Hahn LW, Moore JH. 2003. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 24:150-157.
65. Roses AD, Devlin B, Conneally PM, Small GW, Saunders AM, Pritchard PA, Lock JL, Haines JL, Pericak-Vance MA, Risch N. 1995. Measuring the genetic contribution of APOE in late-onset Alzheimer Disease. Am J Hum Genet 57:A202.
66. Saunders AM, Strittmatter WJ, Breitner JC, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Growden J, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. 1993. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472.
67. Shahani N, Subramaniam S, Wolf T, Tackenberg C, Brandt R. 2006. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J Neurosci 26:6103-6114.
68. Siegmund KD, Langholz B, Kraft P, Thomas DC. 2000. Testing linkage disequilibrium in sibships. Am J Hum Genet 67:244-248.
69. Slooter AJC, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM. 1998. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 55:964-968.
70. Smith CAB. 1963. Testing for heterogeneity of recombination fractions values in human genetics. Ann Hum Genet 27:175-182.
71. Storey JD. 2002. A direct approach to false discovery rates. J R Stat Soc B 64:479-498.
72. Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance MA, Schmechel D, Saunders AM, Goldgaber D, Roses AD. 1993. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102.
73. Thornton-Wells TA, Moore JH, Haines JL. 2004. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 20:640-647.
74. Thornton-Wells TA, Moore JH, Haines JL. 2006. Dissecting trait heterogeneity: a comparison of three clustering methods applied to genotypic data. BMC Bioinform 7:204.
75. Velez DR, White BC, Motsinger AA, Bush WS, Ritchie MD, Williams SM, Moore JH. 2007. A balanced accuracy function for epistasis modeling in unbalanced datasets using multifactor dimensionality reduction. Genet Epidemiol 31:306-315.
76. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. 1993. Apolipoprotein E: binding to soluble Alzheimer betaamyloid. Biochem Biophys Res Commun 192:359-365.
77. Yang Y, Varvel NH, Lamb BT, Herrup K. 2006. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci 26:775-784.